# Nusano

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nusano

- Industry: Medical Devices & Equipment
- Headquarters: Valencia, US
- Website: www.nusano.com
- Total disclosed funding: $23M
- Latest round: Series C (Apr 29, 2024)
- Investors on record: 4

## About

Based in California, US, and founded in 2013 by co-founders Glenn Rosenthal, and Howard Lewin Nusano, Inc. develops advanced molecular technologies to address various medical conditions, including cancer and genetic disorders. In October 2024, Nusano, Inc. raised USD 115 million in Series C funding led by investor Wasatch Equity Partners, BrightEdge Ventures, Section 32, and Verily Life Sciences LLC.

Nusano’s product offering is medical-grade radioisotopes for diagnostic and therapeutic applications in cancer care. These isotopes serve as tracers in imaging technologies, enabling healthcare providers to visualise internal organs and detect abnormalities. The company leverages its proprietary particle beam technology to produce a wide variety of radioisotopes essential for medical diagnostics, advanced pharmaceuticals, and cancer therapies.

The company will use the October 2024 funding to support the launch of its products lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).

## Funding rounds

- Series C, Apr 29, 2024, $23M — Section 32, Verily Life Sciences LLC, BrightEdge Ventures, Wasatch Equity Partners

## Investors

- Section 32 (https://capitalatlas.ai/funds/section-32) — Series C
- Verily Life Sciences LLC — Series C
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series C
- Wasatch Equity Partners (https://capitalatlas.ai/funds/wasatch-equity-partners) — Series C